Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Is  (CODX) Outperforming Other Medical Stocks This Year?

Is CoDiagnostics (CODX) Outperforming Other Medical Stocks This Year?

SAN DIEGO & SALT LAKE CITY--(BUSINESS WIRE)---- $CODX #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 25, 2020 and May 15, 2020. Co-Diagnostics is a molecular diagnostics company that intends to manufacture and sell reagents used for diagnostic tests. If you suffered a loss as a result of Co-Diagnostics' miscond

Shareholder Alert: Robbins LLP Reminds Investors Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Utah on behalf of purchasers of Co-Diagnostics, Inc. (NASDAQ:CODX) securities between February 25, 2020 and May 15, 2020 (the “Class Period”). The case is captioned Gelt Trading, Ltd. v. Co-Diagnostics, Inc., No. 20-cv-00368, and is assigned to Magistrate Judge Cecilia M. Romero. The Co-Diagnostics class action lawsuit charges Co-Diagnostics and certain of its

Notice of Lead Plaintiff Deadline for Shareholders in the Co-Diagnostics, Inc. Class Action Lawsuit

Co-Diagnostics: COVID-19 Test Sales Push Up Its Price

NEW YORK, July 2, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company")(NASDAQ: CODX) and certain of its officers. The class action, filed in United States District Court for the District of...

Pomerantz Law Firm Announces the Filing of a Class Action against Co-Diagnostics, Inc. and Certain Officers - CODX

NEW YORK--(BUSINESS WIRE)---- $CODX #classaction--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of those who acquired Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (NASDAQ: CODX) securities during the period from February 25, 2020 through May 15, 2020. Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The lawsuit alleges that the Company

CODX INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the “Class Period”) of the important August 17, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Co-Diagnostics investors under the federal securities laws. To join the Co-Diagnostics class action, go to http://www.rosenlegal.com/cases-r

CODX LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Co-Diagnostics, Inc. Investors of Important Deadline in Securities Class Action – CODX

New York, New York--(Newsfile Corp. - June 27, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Co-Diagnostics s

Co-Diagnostics Class Action Reminder: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg

CODX SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm

New York, New York--(Newsfile Corp. - June 25, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logo

Co-Diagnostics Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm

Dynavax Technologies

Novavax

VBI Vaccines

Bad news about rising COVID-19 cases is good news for these stocks.

Why Novavax, Dynavax, VBI Vaccines, and Co-Diagnostics Stocks Are Jumping Today

Has CoDiagnostics (CODX) Outpaced Other Medical Stocks This Year?

New York, New York--(Newsfile Corp. - June 23, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logo

Co-Diagnostics  Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm

NEW YORK--(BUSINESS WIRE)---- $CODX #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of those who acquired Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (NASDAQ: CODX) securities during the period from February 25, 2020 through May 15, 2020. Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The lawsuit alleges that the Company made ma

CODX INVESTOR ALERT: Kirby McInerney LLP Announces That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17

NEW YORK, June 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the "Class...

ROSEN, A LEADING NATIONAL FIRM, Announces Filing of Securities Class Action Lawsuit Against Co-Diagnostics, Inc. - CODX

New York, New York--(Newsfile Corp. - June 22, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company") of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logo

Co-Diagnostics Shareholder Alert:   Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm

Co-Diagnostics will be on the move over the next week. Don't confuse a technical trade for a strong long-term investment case in CODX stock.

Co-Diagnostics Stock: Trading the Russell 2000 Index Catalyst

LOS ANGELES--(BUSINESS WIRE)---- $CODX #classaction--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors

LOS ANGELES--(BUSINESS WIRE)---- $CODX #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) securities between February 25, 2020 and May 15, 2020, inclusive (the “Class Period”). Co-Diagnostics investors have until August 17, 2020 to file a lead plaintiff motion. If you are a shareholder who suffered a loss, click here to particip

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc.

NEW YORK, June 19, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of...

CODX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm

Monday's lawsuit hasn't impacted the chart of Co-Diagnostics one bit. Here are the price levels in CODX stock that I'd trade around right now.

Co-Diagnostics Gets Sued, Investors Shrug

CODX stock will start to tumble back to earth as more competitors enter the testing space, and the impact of Covid-19 subsides.
The post Co-Diagnostics Stock Is a Fun Day Trade but It Is No Investment appeared first on InvestorPlace.

Co-Diagnostics Stock Is a Fun Day Trade but It Is No Investment

SALT LAKE CITY, June 9, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is expected to join the Russell 2000® Index at the conclusion of the annual...

Co-Diagnostics, Inc. to Join Russell 2000® and Russell 3000® Indexes

Alpha Pro Tech

Carvana

iBio

Moderna

Shopify

Wayfair

These seven A- and B-rated names are some of the top risky stocks to buy for enterprising investors. Here's what you should know about each company.

7 Risky Stocks That Are Worth a Gamble

CODX stock took a hit as economic indicators suggested a sooner-than-expected recovery. But don’t completely ignore shares just yet.

News for Co-Diagnostics Stock (CODX)